Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Joint contracture is reduced by intra‐articular implantation of rosiglitazone‐loaded hydrogels in a rabbit model of arthrofibrosis
Arsoy, Diren , Salib, Christopher G. , Trousdale, William H. , Tibbo, Meagan E. , Limberg, Afton K. , Lewallen, Eric A. , Reina, Nicolas , Yaszemski, Michael J. , Berry, Daniel J., Wijnen, André J. van , Berry, Daniel J. , Viste, Anthony , Reina, Nicolas , Sanchez-Sotelo, Joaquin, van Wijnen, Andre J , Berry, Daniel J , Berry, Daniel J., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P.

Mayo Clinic

Journal of Orthopaedic Research | June 14, 2018 | Volume: 36 | Issue: 11 | Pages: 2949-2955

10.1002/jor.24068 | PMID 29901247 Get It

ABSTRACTTrauma, surgery, and other inflammatory conditions can lead to debilitating joint contractures. Adjunct pharmacologic modalities may permit clinical prevention and treatment of recalcitrant joint contractures. We investigated the therapeutic potential of rosiglitazone by intra‐articular delivery via oligo[poly(ethylene glycol)fumarate] (OPF) hydrogels in an established rabbit model of arthrofibrosis. OPF hydrogels loaded with rosiglitazone were characterized for drug elution properties upon soaking in minimum essential media (MEM) with 10% fetal bovine serum and measurements of drug concentrations via High Performance Liquid Chromatography (HPLC). Drug‐loaded scaffolds were surgically implanted into 24 skeletally mature female New Zealand White rabbits that were divided into equal groups receiving OPF hydrogels loaded with rosiglitazone (1.67 mg), or vehicle control (10 µl DMSO). After 8 weeks of joint immobilization, rabbits were allowed unrestricted cage activity for 16 weeks. Contracture angles of rabbit limbs treated with rosiglitazone showed statistically significant improvements in flexion compared to control animals (mean angles, respectively, 64.4° vs. 53.3°, p < 0.03). At time of sacrifice (week 24), animals in the rosiglitazone group continued to exhibit less joint contracture than controls (119.0° vs. 99.5°, p = 0.014). The intra‐articular delivery of rosiglitazone using implanted OPF hydrogels decreases flexion contractures in a rabbit model of arthrofibrosis without causing adverse effects (e.g., gross inflammation or arthritis). Statement of Clinical Significance: Post‐traumatic joint contractures are common and debilitating, with limited available treatment options. Pharmacologic interventions can potentially prevent and treat such contractures. This study is translational in that a commercially approved medication has been repurposed through a novel delivery device. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:2949–2955, 2018.
YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity
Werneburg, Nathan W., Hernandez, Matthew C. , Yang, Lin , Kabashima, Ayano , Hirsova, Petra , Yohanathan, Lavanya, Sosa, Carlos, Truty, Mark J. , Vasmatzis, George , Smoot, Rory L. , Sugihara, Takaaki, Hernandez, Matthew C , Hirsova, Petra , Smoot, Rory L , Sugihara, Takaaki , Gores, Gregory J.

Mayo Clinic

Molecular Cancer Research | June 14, 2018 | Volume: 16 | Issue: 10 | Pages: 1556-1567

10.1158/1541-7786.mcr-18-0158 | PMID 29903769 Get It

Abstract The Hippo pathway effector, Yes-associated protein (YAP), is a transcriptional coactivator implicated in cholangiocarcinoma (CCA) pathogenesis. YAP is known to be regulated by a serine/threonine kinase relay module (MST1/2–LATS1/2) culminating in phosphorylation of YAP at Serine 127 and cytoplasmic sequestration. However, YAP also undergoes tyrosine phosphorylation, and the role of tyrosine phosphorylation in YAP regulation remains unclear. Herein, YAP regulation by tyrosine phosphorylation was examined in human and mouse CCA cells, as well as patient-derived xenograft (PDX) models. YAP was phosphorylated on tyrosine 357 (Y357) in CCA cell lines and PDX models. SRC family kinase (SFK) inhibition with dasatinib resulted in loss of YAPY357 phosphorylation, promoted its translocation from the nucleus to the cytoplasm, and reduced YAP target gene expression, including cell lines expressing a LATS1/2-resistant YAP mutant in which all serine residues were mutated to alanine. Consistent with these observations, precluding YAPY357 phosphorylation by site-directed mutagenesis (YAPY357F) excluded YAP from the nucleus. Targeted siRNA experiments identified LCK as the SFK that most potently mediated YAPY357 phosphorylation. Likewise, inducible CRISPR/Cas9-targeted LCK deletion decreased YAPY357 phosphorylation and its nuclear localization. The importance of LCK in CCA biology was demonstrated by clinical observations suggesting LCK expression levels were associated with early tumor recurrence following resection of CCA. Finally, dasatinib displayed therapeutic efficacy in PDX models. Mol Cancer Res; 16(10); 1556–67. ©2018 AACR.
Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients
Wang, Lei , Felts, Sara J. , Keulen, Virginia P. Van , Scheid, Adam D. , Block, Matthew S. , Pease, Larry R. , Zhang, Yuji , Van Keulen, Virginia P , Markovic, Svetomir N.

Mayo Clinic

Cancer Research | June 12, 2018 | Volume: 78 | Issue: 15 | Pages: 4411-4423

10.1158/0008-5472.can-18-0529 | PMID 29895674 Get It

Abstract Genome-wide identification and characterization of long noncoding RNAs (lncRNA) in individual immune cell lineages helps us better understand the driving mechanisms behind melanoma and advance personalized patient treatment. To elucidate the transcriptional landscape in diverse immune cell types of peripheral blood cells (PBC) in stage IV melanoma, we used whole transcriptome RNA sequencing to profile lncRNAs in CD4+, CD8+, and CD14+ PBC from 132 patient samples. Our integrative computational approach identified 27,625 expressed lncRNAs, 2,744 of which were novel. Both T cells (i.e., CD4+ and CD8+ PBC) and monocytes (i.e., CD14+ PBC) exhibited differential transcriptional expression profiles between patients with melanoma and healthy subjects. Cis- and trans-level coexpression analysis suggested that lncRNAs are potentially involved in many important immune-related pathways and the programmed cell death receptor 1 checkpoint pathways. We also identified nine gene coexpression modules significantly associated with melanoma status, all of which were significantly enriched for three mRNA translation processes. Age and melanoma traits closely correlated with each other, implying that melanoma contains age-associated immune changes. Our computational prediction analysis suggests that many cis- and trans-regulatory lncRNAs could interact with multiple transcriptional and posttranscriptional regulatory elements in CD4+, CD8+, and CD14+ PBC, respectively. These results provide novel insights into the regulatory mechanisms involving lncRNAs in individual immune cell types in melanoma and can help expedite cell type-specific immunotherapy treatments for such diseases. Significance: These findings elucidate melanoma-associated changes to the noncoding transcriptional landscape of distinct immune cell classes, thus providing cell type-specific guidance to targeted immunotherapy regimens. Cancer Res; 78(15); 4411–23. ©2018 AACR.
Early Infectious Diseases Specialty Intervention Is Associated With Shorter Hospital Stays and Lower Readmission Rates: A Retrospective Cohort Study
Schmitt, Steven , Macintyre, Ann , Bleasdale, Susan C , Ritter, J Trees, Nelson, Sandra B. , Berbari, Elie F. , Burdette, Steven D., Hewlett, Angela , Siddiqui, Javeed, Trotman, Robin, Martinelli, Lawrence, Zeitlin, Gary, Rodriguez, Andrés , Smith, Mark W. , McQuillen, Daniel P. , Miles, Matthew , Robinson, Philip Alan

Mayo Clinic

Clinical Infectious Diseases | June 11, 2018 | Volume: 68 | Issue: 2 | Pages: 239-246

10.1093/cid/ciy494 | PMID 29901775 Get It

Postexercise Hemodynamic Responses in Lean and Obese Men
Zeigler, Zachary , Swan, Pamela D. , Buman, Matthew P. , Mookadam, Farouk , Angadi, Siddhartha S. , Mookadam, Farouk , Gaesser, Glenn A. , Buman, M. P.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 10, 2018 | Volume: 50 | Issue: 11 | Pages: 2292-2300

10.1249/mss.0000000000001684 | PMID 29889821 Get It

ABSTRACT Purpose We assessed resting central/peripheral blood pressure (BP), postexercise BP, and hemodynamic responses (stroke volume, cardiac output, and systemic vascular resistance) after acute exercise and 2 wk of aerobic training in lean and centrally obese men matched for BP. Methods Eight lean (body mass index < 25 kg·m −2 , visceral fat = 279 ± 224 cm 3 ) and eight centrally obese (body mass index > 30 kg·m −2 , visceral fat = 1471 ± 374 cm 3 ) men performed six training sessions (3 d·wk −1 for 40 min at 65%–70% HR max ). Resting BP and hemodynamic measurements were obtained at baseline, after exercise for 60 min, and at 24 h and 48 h after the last training session. Results Postexercise brachial and central systolic BP (SBP) and mean arterial BP decreased 3–4 mm Hg below resting in lean ( P < 0.001) and increased by 3 mm Hg in obese ( P < 0.02). Posttraining resting brachial/central SBP were reduced by 3–4 mm Hg only in lean men ( P < 0.05). Pretraining postexercise hypotension was significantly correlated with the training-induced change in resting brachial SBP at 48 h ( r = 0.58, P = 0.02), but not at 24 h ( r = 0.38, P = 0.15). Similar correlations were observed between acute reductions in central SBP and central SBP at 24 h ( r = 0.43, P = 0.09) and 48 h ( r = 0.54, P = 0.03) posttraining. Conclusions In contrast to the consistent results for lean men, postexercise hypotension was not observed in centrally obese men, and resting SBP was not reduced after a short aerobic training program. Considerable individual variation in postexercise BP response among obese men may have implications for design of exercise interventions to lower BP in these individuals.
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Pegram, Mark D. , Zong, Yu , Yam, Clinton , Moulder, Stacy , Moulder, Stacy L. , Goetz, Matthew P.

Mayo Clinic

American Society of Clinical Oncology Educational Book | June 8, 2018 | Volume: No volume available | Issue: 38 | Pages: 65-77

10.1200/edbk_200715 | PMID 30231328 Get It

Metastatic breast cancer continues to be a life-threatening diagnosis that impacts hundreds of thousands of patients around the world. Targeted therapies are usually associated with less toxicity compared with cytotoxic chemotherapies and often induce response or durable disease control in estrogen receptor (ER) and/or HER2+ breast cancers. Drugs that target CDK 4/6 either alone or in combination with endocrine therapy have demonstrated substantial improvements in progression-free survival (PFS) compared with endocrine monotherapy. Most recently, PARP inhibitors have shown longer PFS compared with physician’s choice of chemotherapy in BRCA-associated cancers, leading to the first U.S. Food and Drug Administration (FDA) approval of a targeted therapy with the potential to benefit a subgroup of patients with triple-negative breast cancer (TNBC). Finally, newer drug delivery strategies using antibody drug conjugates have also allowed a “targeted approach” to deliver moderate to extremely potent cytotoxins directly to sites of metastatic disease, with less toxicity.
Updates in venous thromboembolism management: evidence published in 2017
Bartlett, Matthew , Bierle, Dennis M. , Saadiq, Rayya A. , Mauck, Karen F. , Daniels, Paul R. , Bartlett, Matthew A

Mayo Clinic

Hospital Practice | June 8, 2018 | Volume: 46 | Issue: 4 | Pages: 183-188

10.1080/21548331.2018.1486676 | PMID 29883230 Get It

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Walker, Brian A. , Mavrommatis, Konstantinos , Wardell, Christopher P. , Ashby, Cody , Bauer, Michael , Davies, Faith E. , Hoering, Antje , Samur, Mehmet , Towfic, Fadi , Flynt, Erin , Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan , Obenauer, John C. , Trotter, Matthew , Auclair, Daniel , Keats, Jonathan J. , Bolli, Niccolò , Fulciniti, Mariateresa , Szalat, Raphaël , Moreau, Philippe , Durie, Brian G.M. , Stewart, A. Keith, Goldschmidt, Hartmut , Sonneveld, Pieter , Miguel, Jesús F. San , Jackson, Graham , Avet‐Loiseau, Hervé , Munshi, Nikhil , Thakurta, Anjan , Morgan, Gareth J. , Moreau, Philippe , Bolli, Niccolo' , San-Miguel, Jesus , Davies, Faith E , Keats, Jonathan J , Walker, Brian A , Morgan, Gareth J , Rosenthal, Adam , Wang, Hongwei , Qu, Pingping , Ortiz, María , Raab, Marc S. , Einsele, Hermann , Lonial, Sagar , Anderson, Kenneth C. , Flynt, Erin , Samur, Mehmet K , Szalat, Raphael

Mayo Clinic

Blood | June 8, 2018 | Volume: 132 | Issue: 6 | Pages: 587-597

10.1182/blood-2018-03-840132 | PMID 29884741 Get It

Key Points Using the largest set of patients with newly diagnosed myeloma, we identified 63 mutated driver genes. We identified oncogenic dependencies, particularly relating to primary translocations, indicating a nonrandom accumulation of genetic hits.
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
Wood, William C., Makower, Della , Lively, Tracy , Saphner, Thomas J. , Keane, Maccon, Gomez, Henry Leonidas, Reddy, Pavan S. , Goggins, Timothy F., Toppmeyer, Deborah , Brufsky, Adam , Hayes, Daniel F. , Dees, Elizabeth Claire , Gómez, Henry , Brufsky, Adam M , Sparano, Joseph A. , Gray, Robert J. , Mayer, Ingrid A. , Goetz, Matthew P. , Pritchard, Kathleen I. , Geyer, Charles E. , Olson, John A. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | June 7, 2018 | Volume: 36 | Issue: 18_suppl | Pages: LBA1-LBA1

10.1200/jco.2018.36.18_suppl.lba1 Get It

LBA1 Background: In hormone receptor (HR)-positive, HER2-negative, axillary node (AN)-negative breast cancer, the 21-gene expression assay (Oncotype DX Recurrence Score [RS]) is prognostic for distant recurrence, prognostic for low recurrence with endocrine therapy alone if low (0-10), and predictive of chemotherapy benefit if high (26 or higher). We performed a prospective, randomized trial of endocrine therapy (ET) versus chemoendocrine therapy (CET) in women with a mid-range RS of 11-25. Methods: Eligibility criteria included women 18-75 years of age with HR-positive, HER2-negative, axillary node (AN)-negative breast cancer and tumors 1.1-5.0 cm in size (or 0.6-1.0 cm and int/high grade) and agreed to have chemotherapy assigned or randomized based on the RS. Women with a mid-range RS (11-25) were randomized to receive ET or CET. The primary endpoint was invasive disease-free survival (iDFS), and the trial was designed to show non-inferiority for ET alone by not rejecting equality (hazard ratio [HR] margin up to 1.322 for omission of chemotherapy, 1-sided type I error rate 10%, type II error rate 5%). The target sample size was adjusted to compensate for non-adherence to randomized treatment, and the protocol-specified final analysis was triggered after 835 iDFS events. Results: Of the 10,253 eligible women enrolled between 4/7/06-10/6/10, 6711 (65.5%) had a RS of 11-25 and adequate information. There were 836 iDFS events at final analysis with a median followup of 90 months. ET was non-inferior to CET for iDFS (HR 1.08, 95% confidence intervals [CI] 0.94, 1.24, p=0.26) in the intention-to-treat (ITT) population. ET was also non-inferior for distant recurrence-free interval (DRFI; HR 1.03, p=0.80), recurrence-free interval (RFI; HR 1.12, p=0.28), and overall survival (OS; HR 0.97, p=0.80). Nine year rates were similar for iDFS (83.3% vs. 84.3%), DRFI (94.5% vs. 95.0%), RFI (92.2% vs. 92.9%), and OS (93.9% vs. 93.8%). Recurrence accounted for 338 (41.6%) the first iDFS event, of which 199 (23.8%) were distant recurrences. Treatment interaction tests were significant for age (iDFS p=0.03; RFI p= 0.02), but not menopause, tumor size, grade, or RS (continuous or RS 11-15, 16-20, 21-25). Conclusions: In women with HR-positive, HER2-negative, AN-negative breast cancer and a RS of 11-25, adjuvant ET was not inferior to CET in the ITT analysis. (Funded by NCI, BCRF, and Komen Foundation.) Clinical trial information: NCT00310180.